CNBX Pharmaceuticals IncOTC Pink - Current Information:CNBX
- LAST PRICE0.0102
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0001/ 100
- Ask / Lots0.0400/ 100
- Open / Previous Close0.0092 / 0.0102
- Day Range
- 52 Week Range
- Volume51
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CNBX Pharmaceuticals Inc | 317.3K | -0.2x | --- |
Integrative Health Technologies Inc | 40.0 | 0.0x | --- |
Health Sciences Group Inc | 18.7K | 0.0x | --- |
Manuka Inc | 235.3K | -0.2x | --- |
Callitas Health Inc | 3.3K | --- | --- |
Notable Labs Ltd | 172.9K | 0.0x | --- |
Company Information
CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
Contact Information
- Headquarters
- #3 Bethesda Metro Center, Suite 700BETHESDA, MD, United States 20814
- Phone
- 877-424-2429
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriel Yariv
- Chief Executive Officer, Director
- Eyal Barad
- Chief Financial Officer
- Uri Ben-Or
- Chief Technology Officer
- Sanja Goldberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $317.3K |
|---|---|
Revenue (TTM) | $230.1K |
Shares Outstanding | 31.1M |
CNBX Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.86 |
EPS | $-0.05 |
Book Value | $-0.09 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -300.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
